The company is manufacturing a commercial-scale powderREV machine following the royalty-bearing commercial license that had a machine purchase deal signed in May last year. Sutro has made a
The company is acquiring InvaGen Pharmaceuticals and Exelan Pharmaceuticals, which had combined sales of more than $225m in the twelve months to June 2015. InvaGen develops, manufactures, markets
GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation and survival. GBR 830 was found to be well tolerated
The 19,000m2 warehouse will have a capacity of around 17,000 pallets and handle all inbound raw materials meant for Novo Nordisk’s production in Denmark. Currently, Novo Nordisk’s facility
This is an effort by Pfizer, which manufactures arthritis pill Celebrex, Prevnar pneumococcal vaccines and the fibromyalgia drug Lyrica, to gain a leading position in the global market
The strategic alliance is aimed at developing new cancer immunotherapies based on Cellectis’ allogeneic chimeric antigen receptor (CAR) platform. MD Anderson Cancer Center’s leukemia and myeloma teams will
The regulatory authority has approved Brilinta tablets at a new dose that could be taken along with aspirin beyond a year of heart attack, reported Reuters. In July
Daiichi Sankyo will pay AstraZeneca an undisclosed upfront fee as well as development milestones and sales-associated payments after its launch. The Japanese firm will also take full responsibility
It can be used to treat secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. The company said if approved, etelcalcetide will be
The approval is based on four trials of patients receiving emetogenic chemotherapy, including cisplatin, carboplatin and anthracycline/cyclophosphamide-based regimens. Varubi is a selective and competitive antagonist of human substance
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.